Andere talen Diamyd Medical AB

Aandelen

DMYD B

SE0005162880

Beurs gesloten - Nasdaq Stockholm Andere beurzen 17:29:35 03-05-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
11,16 ^SEK	+4,30%		-6,22%	+69,86%

12/04	Mijlpaal in Diamyd® Fase 3 studie bereikt	CI
27/03	Diamyd Medical AB (publ) rapporteert resultaten voor het tweede kwartaal en de zes maanden eindigend op 29 februari 2024	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Diamyd Medical Raises SEK57 Million in Rights Issue	18/04
Diamyd Medical announces final outcome in the company's rights issue	18/04
Diamyd Medical announces preliminary outcome in the company's rights issue	16/04
Recruitment milestone reached in Diamyd® Phase 3 trial	12/04
Recruitment Milestone Reaches in Diamyd® Phase 3 Trial	12/04
Diamyd Medical led ASSET innovation partnership organizes a workshop on the future treatment of Type 1 Diabetes	11/04
Diamyd Medical's main Shareholders announce their subscription commitments in the ongoing rights issue	05/04
Diamyd Medical publishes prospectus with regards to the rights issue	28/03
Quarterly Report II 23/24	27/03
Diamyd Medical AB Reports Earnings Results for the Second Quarter and Six Months Ended February 29, 2024	27/03
Diamyd Medical to Raise SEK114 Million Via Share Offering	19/03
The Board of Directors in Diamyd Medical have resolved on a rights issue of approximately SEK 114 million	18/03
Diamyd Medical to present new genetic data at the ASIT summit in Boston, MA	29/02
Diamyd Medical to Present New Genetic Data at the ASIT Summit in Boston, MA	29/02
Diamyd Medical Secures US FDA Fast Track Designation for Type 1 Diabetes Treatment	15/02
Diamyd Medical receives U.S. FDA Fast Track designation for Diamyd®	15/02
Publication in Diabetologia highlights AI's potential for Type 1 Diabetes screening	14/02
In-depth analysis of Diamyd® Phase II trial further supports value of preserved insulin secretion	24/01
In-Depth Analysis of Diamyd Medical AB's Phase II Trial Further Supports Value of Presented Insulin Production	24/01
Quarterly Report I 23/24	24/01

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Diamyd Medical AB

Aandelen

DMYD B

SE0005162880

Andere talen

Filters